Background and Release of Post-Market Requirement Reports

The U.S. Food and Drug Administration (FDA) annually publishes the status of post-marketing studies and clinical trials required or agreed upon with new drug and biologics manufacturers, as mandated by the Food and Drug Administration Modernization Act (FDAMA) of 1997. This information is made available in the Federal Register. The recently released report is based on data from Fiscal Year 2024 (FY 2024) and demonstrates the regulatory agency's commitment to continuously monitoring the safety and efficacy of drugs even after their release, thereby protecting patients. Investors and the pharmaceutical industry utilize this report as a key indicator for evaluating the long-term risk management capabilities of new drugs post-approval.

Key Data Analysis of 2024 Fiscal Year Compliance Rate

The report indicates that approximately 70% (1,147 out of 1,636) of the outstanding Post-Marketing Requirement (PMR) studies currently being conducted by manufacturers are progressing smoothly and on schedule. Furthermore, 80% (307 out of 386) of the Post-Marketing Commitments (PMC), which are voluntary commitments made by companies, are also being implemented as planned. However, the on-time submission rate for Annual Status Reports (ASR), which must be submitted within 60 days of the drug's approval anniversary, shows some variation, with 80% for New Drug Applications (NDA) and 72% for Biologics License Applications (BLA).

Impact of Post-Marketing Studies on the Pharmaceutical and Biotechnology Industry

Post-marketing studies (PMR/PMC) are not merely recommendations from regulatory agencies but essential steps that must be taken to demonstrate the actual clinical efficacy of drugs that have received Accelerated Approval or to expand indications, such as pediatric labeling. Delays due to issues with clinical trial design or patient recruitment can lead to Warning Letters and, in the worst-case scenario, market withdrawal, which can have a direct negative impact on a company's value. In particular, the increasing stringency of regulatory agencies regarding the failure to demonstrate clinical efficacy for conditionally approved drugs has further increased the value of this data.

Risk Management for Investors and Companies

Pharmaceutical companies must invest significant resources in post-marketing studies even after approval; therefore, they must carefully calculate these regulatory compliance costs from the early stages of research and development. Investors are also carefully examining the number and schedule of post-marketing studies that must be conducted after approval, in addition to the value of the pipeline, to quantify potential cost burdens and risks. For small and medium-sized biotechnology companies with limited regulatory compliance capabilities, failures or delays in post-marketing studies can trigger a sharp decline in stock prices, so it is essential to continuously monitor the company's detailed implementation plans.

Adoption of Digital Technology and Future Regulatory Prospects

In the future, efforts to improve the efficiency of post-marketing studies through the use of digital health technology (DHT) and real-world data (RWD) are expected to become more active. The FDA has already established a data-sharing platform and introduced quantitative indicators to transparently track and evaluate companies' compliance. In this changing landscape, pharmaceutical companies must strengthen the expertise of their Regulatory Science departments and develop more scientific data acquisition strategies to ensure market survival.